放射性配体疗法的未来：α、β，还是两者兼具？ - Suppr

Suppr

超能文献

The Future of Radioligand Therapy: α, β, or Both?

作者信息

Haberkorn Uwe, Giesel Frederik, Morgenstern Alfred, Kratochwil Clemens

机构信息

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; and.

出版信息

J Nucl Med. 2017 Jul;58(7):1017-1018. doi: 10.2967/jnumed.117.190124. Epub 2017 Apr 13.

DOI:10.2967/jnumed.117.190124

PMID:28408527

Abstract

摘要

相似文献

The Future of Radioligand Therapy: α, β, or Both?放射性配体疗法的未来：α、β，还是两者兼具？

J Nucl Med. 2017 Jul;58(7):1017-1018. doi: 10.2967/jnumed.117.190124. Epub 2017 Apr 13.

The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?用于小肿瘤放射免疫治疗的最佳放射性核素：β发射体还是α发射体？

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):271-3. doi: 10.1007/s00259-010-1707-7.

More α Than β for Prostate Cancer?前列腺癌中α比β更多？

J Nucl Med. 2017 Nov;58(11):1709-1710. doi: 10.2967/jnumed.117.198333. Epub 2017 Sep 21.

Ac-225 and her daughters: the many faces of Shiva.锕-225及其子核素：湿婆的诸多面孔。

Cell Death Differ. 2002 Jun;9(6):593-4. doi: 10.1038/sj.cdd.4401047.

Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.靶向α与靶向β治疗癌症的全球比较：体外、体内和临床试验。

Crit Rev Oncol Hematol. 2018 Mar;123:7-20. doi: 10.1016/j.critrevonc.2018.01.001. Epub 2018 Jan 10.

Therapeutic Radiometals Beyond Lu and Y: Production and Application of Promising α-Particle, β-Particle, and Auger Electron Emitters.镥和钇之外的治疗性放射性金属：有前景的α粒子、β粒子和俄歇电子发射体的生产与应用

J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S. doi: 10.2967/jnumed.116.186825.

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).在人前列腺癌模型中 α-与 β-粒子放射性核素肽治疗的比较（213Bi-DOTA-PESIN 和 213Bi-AMBA 与 177Lu-DOTA-PESIN）。

Cancer Res. 2011 Feb 1;71(3):1009-18. doi: 10.1158/0008-5472.CAN-10-1186. Epub 2011 Jan 18.

A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.一种独特的铽放射性同位素四联体，用于 PET 和 SPECT 以及用于 α 和 β 放射性核素治疗：一种新的受体靶向叶酸衍生物的体内概念验证研究。

J Nucl Med. 2012 Dec;53(12):1951-9. doi: 10.2967/jnumed.112.107540. Epub 2012 Nov 8.

α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.α 发射器在放射治疗中的应用：从基础放射化学到临床研究 - 第 2 部分。

J Nucl Med. 2018 Jul;59(7):1020-1027. doi: 10.2967/jnumed.117.204651. Epub 2018 Mar 1.

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.225Ac-PSMA-617用于转移性去势抵抗性前列腺癌的PSMA靶向α放射治疗。

J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.

引用本文的文献

Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers.用于HER2过表达癌症靶向治疗的、曲妥珠单抗偶联物与放射性金纳米颗粒的放射生物共轭物

Mol Pharm. 2025 Jul 7;22(7):4019-4031. doi: 10.1021/acs.molpharmaceut.5c00288. Epub 2025 May 29.

Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.血液系统恶性肿瘤的诊疗一体化：诊断与靶向治疗的前沿进展

Cancers (Basel). 2025 Apr 7;17(7):1247. doi: 10.3390/cancers17071247.

Clinical application of targeted α-emitter therapy in gastroenteropancreatic neuroendocrine neoplasms.靶向α发射体疗法在胃肠胰神经内分泌肿瘤中的临床应用

J Gastroenterol. 2025 Apr 12. doi: 10.1007/s00535-025-02241-z.

JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.在前列腺特异性膜抗原（PSMA）靶向成像过程中，JHU - 2545能优先保护唾液腺和肾脏。

Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1631-1641. doi: 10.1007/s00259-024-07044-7. Epub 2025 Jan 2.

Effect of molar dose on the in vivo tissue biodistribution profile of FAP-targeted radioligand therapeutics.摩尔剂量对FAP靶向放射性配体治疗药物体内组织生物分布特征的影响。

Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1399-1405. doi: 10.1007/s00259-024-06969-3. Epub 2024 Nov 12.

Novel astatine (At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model.具有新戊二醇结构的新型砹（At）标记的前列腺特异性膜抗原配体：使用前列腺癌异种移植模型评估其稳定性、疗效和安全性。

Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):469-481. doi: 10.1007/s00259-024-06945-x. Epub 2024 Oct 12.

Role of Lutetium Radioligand Therapy in Prostate Cancer.镥放射性配体疗法在前列腺癌中的作用。

Cancers (Basel). 2024 Jul 1;16(13):2433. doi: 10.3390/cancers16132433.

Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.前列腺癌中前列腺特异性膜抗原（PSMA）表达、调控及异质性的生物学决定因素

Nat Rev Urol. 2025 Jan;22(1):26-45. doi: 10.1038/s41585-024-00900-z. Epub 2024 Jul 8.

Actinium-225 targeted alpha particle therapy for prostate cancer.钍 225 靶向 α 粒子治疗前列腺癌。

Theranostics. 2024 May 11;14(7):2969-2992. doi: 10.7150/thno.96403. eCollection 2024.

Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice.Lu-PSMA-617 在转移性去势抵抗性前列腺癌中的应用：证据回顾及对加拿大临床实践的启示。

Curr Oncol. 2024 Mar 7;31(3):1400-1415. doi: 10.3390/curroncol31030106.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验